Clinical evidence reveals dynamic GLUT regulation during treatment: neoadjuvant chemotherapy downregulates GLUT4 in GC patients, coinciding with acquired chemoresistance through PI3K/AKT pathway activation (99, 100). The gene discussed is SLC2A1; the disease is gastric cancer.